Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-582949
BMS-582949 and Methotrexate · 4 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| Placebo + background low to moderate dose statin | ACTIVE_COMPARATOR | Placebo + background low to moderate dose statin Tablets, Oral, 0 mg, once daily, for 12 weeks |
| BMS-582949 + Background low to moderate dose statin | EXPERIMENTAL | BMS-582949 + Background low to moderate dose statin Tablets, Oral, 100 mg, once daily for 12 weeks |
| Atorvastatin | ACTIVE_COMPARATOR | Atorvastatin Tablets, oral, 80 mg once daily for 12 weeks |
| A1 | EXPERIMENTAL | - |
| P1 | PLACEBO_COMPARATOR | - |
| A2 | ACTIVE_COMPARATOR | 30 mg |
| A3 | ACTIVE_COMPARATOR | 100 mg |
| Name | Type | Description |
|---|---|---|
| Placebo | OTHER | - |
| BMS-582949 | DRUG | - |
| Atorvastatin | DRUG | - |
| Statin | DRUG | - |
| BMS-582949 and Methotrexate | DRUG | - |
Inclusion Criteria: * History of documented atherosclerosis * LDL between 70 and 130 mg/dL * Patients receiving stable low- to moderate-dose statin * BMI 18-37 kg/m² * Must be able to swallow tablets * Must be able to medically tolerate the procedures, contrast medium, and medications involved Exc...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
BMS-582949 is an investigational small molecule developed by Bristol-Myers Squibb. It has been studied in combination with methotrexate, a standard rheumatoid arthritis therapy, in clinical trials for rheumatoid arthritis. The combination was evaluated in a Phase 2 proof-of-concept study and a Phase 1 multiple ascending dose study.
BMS-582949 has been studied for rheumatoid arthritis, psoriasis, and vascular diseases. It was tested both as monotherapy and with methotrexate background therapy. All trials were Phase 1 or Phase 2 and have been completed. It is not approved for any indication.
BMS-582949 targets MAPK14, also known as p38 alpha mitogen-activated protein kinase. It acts as an inhibitor of this enzyme. By inhibiting MAPK14, the drug aims to reduce inflammatory signaling, which is relevant to conditions such as rheumatoid arthritis and psoriasis.
BMS-582949 is developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company sponsored the clinical trials evaluating the drug in rheumatoid arthritis, psoriasis, and vascular diseases.
BMS-582949 is in Phase 2 development. It has completed Phase 1 and Phase 2 trials, including a Phase 2 proof-of-concept study in rheumatoid arthritis with methotrexate and a Phase 2 study in plaque psoriasis. It is investigational and has not been approved by the FDA.
BMS-582949 has been evaluated in completed trials including NCT00605735, a Phase 2 study in rheumatoid arthritis with methotrexate; NCT00570752, a Phase 2 study in atherosclerosis; NCT00399906, a Phase 2 study in plaque psoriasis; and NCT00162292, a Phase 1 multiple ascending dose study in rheumatoid arthritis.